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AMC

:   amoxicillin‐clavulanate

AMP

:   ampicillin

CEF

:   cephalexin

CLSI

:   Clinical and Laboratory Standards Institute

MIC

:   minimal inhibitory concentration

MIC~90~

:   90th percentile of minimal inhibitory concentrations

UTI

:   urinary tract infection

1. INTRODUCTION {#jvim15674-sec-0007}
===============

Empirical antimicrobial treatment often is required to manage urinary tract infections (UTI) in veterinary patients, specifically for infections diagnosed by urinalysis or pending the results of culture and antimicrobial susceptibility testing. Making an educated antimicrobial choice to guide early treatment can decrease discomfort and minimize risk of ascending infection. Empirical treatment can be aided by urine sediment findings, prior history of UTI and response to treatment, knowledge of veterinary uropathogens, understanding of antimicrobial pharmacokinetics and pharmacodynamics, and review of consensus statements. Using evidence‐based medicine to choose an antimicrobial likely to be effective the first time not only benefits the patient but also achieves overall stewardship goals of improving appropriate antimicrobial prescribing.[1](#jvim15674-bib-0001){ref-type="ref"}

Antibiograms are a stewardship tool, both in human and veterinary medicine, to provide clinicians with updated information on local resistance patterns for bacterial isolates to help guide and improve successful treatment of various infections.[2](#jvim15674-bib-0002){ref-type="ref"}, [3](#jvim15674-bib-0003){ref-type="ref"} In veterinary medicine, antimicrobial guideline statements, such as those available for UTIs, respiratory disease, and pyoderma, clarify that regional differences in susceptibility should be considered by veterinarians when deciding on the most appropriate antimicrobial protocol for a particular patient.[4](#jvim15674-bib-0004){ref-type="ref"}, [5](#jvim15674-bib-0005){ref-type="ref"}, [6](#jvim15674-bib-0006){ref-type="ref"}, [7](#jvim15674-bib-0007){ref-type="ref"}

Our objectives were to create antibiograms of urinary *Escherichia coli* isolates recovered from cats and dogs at the Kansas State Veterinary Diagnostic Laboratory from 2013 to 2017. These antibiograms then would be available as a regional stewardship tool to help guide evidence‐based decisions on empirical treatment for UTIs for veterinary patients.

2. MATERIALS AND METHODS {#jvim15674-sec-0008}
========================

Ours was a retrospective review of aerobic urine culture results of cats and dogs from the Kansas State Veterinary Diagnostic Laboratory between 2013 and 2017. Diagnostic results were used to create antibiograms for *E. coli* urinary isolates from cats and dogs according to Clinical and Laboratory Standards Institutes (CLSI) guidelines.[2](#jvim15674-bib-0002){ref-type="ref"} Feline and canine urine samples originating from both the Kansas State University Veterinary Health Center and regional midwestern private veterinary practices were eligible for inclusion in the study. Any feline and canine urine sample from which *E. coli* was isolated was included in the study, regardless of colony forming units per milliliter. Only the first positive culture per calendar year from an individual animal was included in the data set. Data collected included species (feline versus canine), year isolated, origination of sample (university versus private practice), and both minimal inhibitory concentration (MIC) and interpretive category (susceptible, intermediate, or resistant) for 10 antimicrobial agents. An antimicrobial panel change occurred in the diagnostic laboratory in mid‐2016, adding cephalexin (CEF), orbifloxacin, and pradofloxacin. Because of the retrospective nature of the study, data regarding previous antimicrobial treatment and comorbidities were not consistently available.

Urine specimen handling before arrival at the laboratory was not standardized, but urine samples were plated within 4 hours of arrival. Culture, isolation, and identification procedures were conducted according to laboratory standard‐operating procedure at the time of specimen submission but varied slightly over the course of this retrospective analysis. All urine specimens initially were plated on trypticase soy (with 5% sheep blood) agar and MacConkey agar using a 10 μL calibrated loop. Cultures were incubated overnight (18‐24 hours) at 37°C in 5% CO~2~. Individual colonies with phenotypic appearance for any uropathogen were streaked for isolation onto nonselective agar, and isolates were identified using 1 of 2 automated systems. From January 2013 to June 2013, isolates were identified using the Omnilog system (Biolog, Hayward, California). From July 2013 through 2017, bacterial identification was performed using matrix‐assisted laser desorption ionization time‐of‐flight mass spectrometry (Bruker BioTyper, Billerica, Massachusetts).

Antimicrobial susceptibility was performed using microwell dilution testing according to CLSI recommendations, using the breakpoints listed in Table [1](#jvim15674-tbl-0001){ref-type="table"}.[8](#jvim15674-bib-0008){ref-type="ref"}, [9](#jvim15674-bib-0009){ref-type="ref"}, [10](#jvim15674-bib-0010){ref-type="ref"} When breakpoints were not available for *E. coli* UTIs for isolates from cats and dogs specifically, breakpoints for UTIs in dogs were used for cefpodoxime and CEF in cats, soft tissue infection breakpoints were used for fluoroquinolones in cats, and non‐site specific *Enterobacteriaceae* breakpoints for humans were used for trimethoprim‐sulfamethoxazole for both isolates from cats and dogs.[8](#jvim15674-bib-0008){ref-type="ref"}, [9](#jvim15674-bib-0009){ref-type="ref"} Antibiograms were created by calculating the percentage of isolates susceptible to each antimicrobial agent; isolates reported as intermediate were not considered susceptible.[8](#jvim15674-bib-0008){ref-type="ref"} The 90th percentile of minimal inhibitory concentrations (MIC~90~) was calculated for isolates recovered from submissions from cats and dogs.[11](#jvim15674-bib-0011){ref-type="ref"} A chi‐square test with Yates correction was performed to test the proportion of isolates reported susceptible (versus not susceptible) between university and private practice populations for antimicrobials that appeared to have discordant results; significance was set at *P* \< .05.

###### 

Breakpoints used to create antibiograms for urinary *Escherichia coli* isolates from cats and dogs, as recommended from Clinical and Laboratory Standards Institute

                                  Minimal inhibitory concentration breakpoints (μg/mL)                                                                                                                         
  ------------------------------- ------------------------------------------------------ ---------- ---------- ----------------------------------------------------------------------- ------- ------- ------- ---------------------------------------------------------
  Amoxicillin/clavulanate         ≤0.25/0.12                                             0.5/0.25   ≥1.0/0.5   Feline UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]                 ≤8/4    N/A     ≥16     Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]
  Ampicillin                      ≤0.25                                                  0.5        ≥1.0       Feline UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]                 ≤8      N/A     ≥16     Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]
  Cefovecin                       ≤2                                                     4          ≥8         Feline UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]                 ≤2      4       ≥8      Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]
  Cefpodoxime                     ≤2                                                     4          ≥8         Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]                 ≤2      4       ≥8      Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]
  Cephalexin                      ≤16                                                    N/A        ≥32        Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]                 ≤16     N/A     ≥32     Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]
  Enrofloxacin                    ≤0.5                                                   1‐2        ≥4         Feline skin/soft tissue \[[8](#jvim15674-bib-0008){ref-type="ref"}\]    ≤0.5    1‐2     ≥4      Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]
  Marbofloxacin                   ≤1                                                     2          ≥4         Feline skin/soft tissue \[[8](#jvim15674-bib-0008){ref-type="ref"}\]    ≤1      2       ≥4      Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]
  Orbifloxacin                    ≤1                                                     2‐4        ≥8         Feline skin/soft tissue \[[8](#jvim15674-bib-0008){ref-type="ref"}\]    ≤1      2‐4     ≥8      Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]
  Pradofloxacin                   ≤0.25                                                  0.5‐1      ≥2         Feline skin, respiratory \[[8](#jvim15674-bib-0008){ref-type="ref"}\]   ≤0.25   0.5‐1   ≥2      Canine UTI \[[8](#jvim15674-bib-0008){ref-type="ref"}\]
  Trimethoprim/sulfamethoxazole   ≤2/38                                                  N/A        ≥4/76      Human \[[9](#jvim15674-bib-0009){ref-type="ref"}\]                      ≤2/38   N/A     ≥4/76   Human \[[9](#jvim15674-bib-0009){ref-type="ref"}\]

Abbreviations: I, intermediate; N/A, not applicable; R, resistant; S, susceptible.

3. RESULTS {#jvim15674-sec-0009}
==========

Six‐hundred forty urinary *E. coli* isolates were recovered from dogs, with 273 (43%) from the university and 367 (57%) from private practice. One‐hundred forty‐three urinary *E. coli* isolates were recovered from cats, with 62 (43%) from the university and 81 (57%) from private practice. Despite efforts to exclude patients with \>1 submission in a calendar year, 2 isolates from cats (1.4%) and 11 isolates from dogs (1.7%) were considered possible repeats but were included because of unconfirmed identification and lack of unique patient identifiers.

Antibiogram results for urinary *E. coli* isolates from cats and dogs are listed in Table [2](#jvim15674-tbl-0002){ref-type="table"}. No isolates from cats were reported susceptible to amoxicillin‐clavulanate (AMC) or ampicillin (AMP), a surrogate for amoxicillin. Among the isolates from dogs, susceptibility to AMC was high (92%) but susceptibility to amoxicillin, a surrogate for amoxicillin, was lower (53%). Minimal inhibitory concentration distributions for AMC for isolates from cats and dogs are presented in Figures [1](#jvim15674-fig-0001){ref-type="fig"} and [2](#jvim15674-fig-0002){ref-type="fig"}. The MIC~90~ of urinary *E. coli* isolates from both cats and dogs for AMC was 8 μg/mL. Resistance in isolates from cats and dogs to other antimicrobials was uncommon (Table [2](#jvim15674-tbl-0002){ref-type="table"}), with \<6% of isolates from cats and \<14% of isolates from dogs showing resistance to any other antimicrobial agent.

###### 

Urinary antibiograms for cats and dogs from 2013 to 2017 reporting percent susceptibility among urinary *Escherichia coli* isolates from cats and dogs originating from either the university hospital or private practices to 10 antimicrobial agents

  Antimicrobial   N     AMC (%)   AMP (%)[a](#jvim15674-note-0003){ref-type="fn"}   CFV (%)   CPD (%)   CEF (%)[b](#jvim15674-note-0004){ref-type="fn"}   ENR (%)   MBF (%)   ORF (%)[b](#jvim15674-note-0004){ref-type="fn"}   PRF (%)[b](#jvim15674-note-0004){ref-type="fn"}   SXT (%)
  --------------- ----- --------- ------------------------------------------------- --------- --------- ------------------------------------------------- --------- --------- ------------------------------------------------- ------------------------------------------------- ---------
  Feline total    143   0         0                                                 93        94        99                                                96        96        97                                                97                                                96
  University      62    0         0                                                 94        94        100                                               95        95        96                                                96                                                97
  Private         81    0         0                                                 93        94        98                                                96        96        98                                                98                                                96
  Canine total    640   92        53                                                87        86        86                                                90        91        89                                                90                                                92
  University      273   92        63                                                85        84        84                                                90        91        90                                                90                                                92
  Private         367   92        46                                                88        88        88                                                89        91        88                                                90                                                92

Abbreviations: AMC, amoxicillin‐clavulanate; AMP, ampicillin; CEF, cephalexin; CFV, cefovecin; CPD, cefpodoxime; ENR, enrofloxacin; MBF, marbofloxacin; ORF, orbifloxacin; PRF, pradofloxacin; SXT, trimethoprim‐sulfamethoxazole.

Indicates a significant difference in proportion of canine isolates that were reported susceptible (versus not susceptible) to AMP from the university versus private practice populations (*P* \< .001).

Indicates that sample size is lower for cephalexin, orbifloxacin, and pradofloxacin (85 total feline, 302 total canine) because the laboratory panel was changed in 2016 to add cephalexin and these fluoroquinolones.

![Distribution of minimal inhibitory concentration (μg/mLs) for amoxicillin‐clavulanate among urinary *Escherichia coli* isolates from cats (N = 143). The dashed vertical lines represent the CLSI breakpoints, with susceptible isolates having MIC ≤0.25 μg/mL and resistant isolates ≥1 μg/mL. Black bars represent isolates submitted from private practices and white bars represent isolates submitted from the university hospital](JVIM-34-227-g001){#jvim15674-fig-0001}

![Distribution of minimal inhibitory concentration (μg/mL) for amoxicillin‐clavulanate among urinary *Escherichia coli* isolates from dogs (N = 640). The dashed vertical line represents the CLSI breakpoint for urinary tract infections, with susceptible isolates having MIC ≤8 μg/mL. Black bars represent isolates submitted from private practices and white bars represent isolates submitted from the university hospital](JVIM-34-227-g002){#jvim15674-fig-0002}

When comparing between university and private practice isolates from both cats and dogs, percentages of isolates susceptible to each antimicrobial were numerically similar (Table [2](#jvim15674-tbl-0002){ref-type="table"}). The exception was AMP in dogs, where more isolates from dogs from the university hospital (172/273, 63%) population were susceptible to AMP than from the private practice (169/367, 46%) population; this difference was significant (*P* \< .001).

4. DISCUSSION {#jvim15674-sec-0010}
=============

A high level of resistance was reported among urinary *E. coli* isolates from cats to ampicillin and AMC, compared with isolates from dogs. With a similar MIC distribution and MIC~90~ between isolates of cats and dogs, this discrepancy likely is reflective of the application of different (higher) breakpoints for UTIs in dogs (S ≤ 8 μg/mL), but not in cats (S ≤ 0.25 μg/mL). Rather than viewing these data as a reason to avoid prescribing amoxicillin and AMC, both first‐line antimicrobial agents recommended in the guidelines for empirical treatment of UTIs in cats and dogs,[5](#jvim15674-bib-0005){ref-type="ref"} our study emphasizes the need to reevaluate the breakpoint used to determine susceptibility in cats.

Beta lactam antimicrobials are recognized to have good penetration into the urine, yet published data on concentrations for amoxicillin and AMC in feline urine have not been reported. Therefore, ampicillin and AMC breakpoints in cats were determined from plasma drug concentrations, as compared to UTI‐specific breakpoints in dogs based on urine concentration data.[8](#jvim15674-bib-0008){ref-type="ref"} Consequently, ampicillin and AMC breakpoint for cats are conservative (low), resulting in more isolates from cats being reported resistant than isolates from dogs, despite the populations having very similar MIC distributions. Determination of urine concentration data for these antimicrobials in cats would support the development of a UTI‐specific breakpoint for cats.

A less conservative, UTI‐specific breakpoint for *E. coli* infections in cats would increase the percentage of isolates reported as susceptible, and veterinarians would have additional therapeutic options for successfully managing these UTIs with PO, affordable, first‐line antimicrobial agents. For example, if the breakpoint of S ≤ 8 μg/mL in dogs was applied to the population of isolates from cats in our study, the percentage of isolates from cats reported susceptible would increase from 0 to 89% for AMP, and from 0 to 99% for AMC. The data set for our study did not delineate isolates from cases of subclinical bacteriuria versus clinical UTI, nor from azotemic versus non‐azotemic cats; thus, these results might not apply to each of these populations of cats similarly. Ideally, unique antibiograms would be created for each of these populations to allow clinicians to make the most appropriate conclusions and therapeutic decisions.

A study comparing susceptibility of *E. coli* UTI isolates from cats and dogs throughout Europe had very similar findings to ours, with 0% susceptibility to AMC among isolates from cats, with an MIC~90~ of 8 μg/mL, when using the same breakpoint of S ≤ 0.25 μg/mL.[12](#jvim15674-bib-0012){ref-type="ref"} In that study, however, the breakpoint for ampicillin used was the breakpoint from dogs (S ≤ 8 μg/mL), thus they found 81.3% susceptibility despite MIC~90~ \>32 μg/mL.[12](#jvim15674-bib-0012){ref-type="ref"} This highlights the importance of noting the exact breakpoint used when reviewing susceptibility data, the challenges of comparing antibiograms and susceptibility results among studies, and the need for universal feline‐specific UTI breakpoints.

It was also noteworthy that among the urinary *E. coli* isolates from dogs in our study, susceptibility to ampicillin (53%) was decreased compared with AMC (92%). This finding could suggest to regional veterinarians that AMC might be a better empirical choice than amoxicillin for treatment of *E. coli* UTIs in dogs. Although a regional finding, it emphasizes the need for evidence‐based research to determine whether a benefit might exist for treating UTIs in dogs with AMC rather than amoxicillin alone.[4](#jvim15674-bib-0004){ref-type="ref"}, [5](#jvim15674-bib-0005){ref-type="ref"} For comparison, in the study from Europe, 79% of *E. coli* UTI isolates from dogs were susceptible to AMP, whereas 98% were susceptible to AMC.[12](#jvim15674-bib-0012){ref-type="ref"} The potential confounding effect of prior antimicrobial treatment should be taken into consideration when interpreting these results and making treatment decisions for future canine patients. Decisions for empirical treatment ideally would be made based on regional antibiograms from patients having received no prior antimicrobial treatment. Without these historical data, it is unclear to what extent ampicillin resistance seen in isolates from dogs in our study was influenced by previous beta‐lactam exposure. This population could have been skewed with a higher proportion of isolates from cats and dogs with a history of beta‐lactam antimicrobial use or of those having received multiple antimicrobial courses leading to greater resistance, because aerobic urine cultures might have been submitted more often in animals with recurrent UTI or previous therapeutic failure.

Our study also was limited by its retrospective nature which did not allow for consistent handling of urine samples before submission or for consistent time between urine collection and plating, because specimen shipment was required for most of the private practice submissions. It is also possible that, despite efforts, \>1 urine sample per animal was included in the data set, but this would represent \<2% of samples if it occurred and thus would have limited impact on the clinical interpretation of the results. Medical records were not reviewed to identify clinical signs and information on urine collection method, and all positive samples were included without consideration for bacterial load (colony forming units). Therefore, distinguishing among subclinical bacteriuria, contamination, and infection was not possible. In the future, exclusion of subclinical bacteriuria when determining antibiograms could be beneficial for stewardship efforts.

Our results highlight the importance of understanding the relevance of antibiogram development on individual patient management. Factors, such as specimen origin (practice type in our study), geographical location, and which interpretive criteria (breakpoints) are applied can impact cumulative antimicrobial susceptibility testing data. Additional factors such as whether isolates come from clinical or subclinical and healthy or azotemic patients also may influence antibiogram results and applicability to individual patients. Although the current findings may not reflect the prevalence of *E. coli* antimicrobial resistance in other parts of the United States, these results can be used as part of an overall veterinary antimicrobial stewardship plan by guiding the selection of empirical antimicrobial treatment for UTIs in dogs and cats in the Midwestern United States.
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